Deciphera Pharmaceuticals (NASDAQ:DCPH) Earns Hold Rating from Jefferies Financial Group

Jefferies Financial Group reissued their hold rating on shares of Deciphera Pharmaceuticals (NASDAQ:DCPH) in a research report released on Monday, Benzinga reports. Jefferies Financial Group currently has a $25.60 price target on the stock, down from their prior price target of $26.00.

Several other equities research analysts also recently commented on the company. JPMorgan Chase & Co. increased their price objective on Deciphera Pharmaceuticals from $14.00 to $16.00 and gave the company a neutral rating in a report on Wednesday, March 20th. Jonestrading reiterated a hold rating and issued a $25.60 price target on shares of Deciphera Pharmaceuticals in a research note on Monday. Finally, Stifel Nicolaus raised their target price on shares of Deciphera Pharmaceuticals from $22.00 to $23.00 and gave the company a buy rating in a research note on Wednesday, February 7th. Seven analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. According to data from MarketBeat, Deciphera Pharmaceuticals has a consensus rating of Hold and an average target price of $24.17.

Deciphera Pharmaceuticals Trading Up 0.4 %

Deciphera Pharmaceuticals stock opened at $25.36 on Monday. Deciphera Pharmaceuticals has a 1-year low of $9.90 and a 1-year high of $25.40. The company has a fifty day simple moving average of $16.18 and a 200 day simple moving average of $14.63. The company has a market cap of $2.09 billion, a P/E ratio of -11.07 and a beta of 0.39.

Deciphera Pharmaceuticals (NASDAQ:DCPH) last announced its quarterly earnings data on Tuesday, February 6th. The company reported ($0.54) earnings per share for the quarter, beating the consensus estimate of ($0.58) by $0.04. Deciphera Pharmaceuticals had a negative return on equity of 49.44% and a negative net margin of 119.33%. The company had revenue of $48.30 million during the quarter, compared to analysts’ expectations of $45.93 million. During the same quarter last year, the company earned ($0.60) EPS. Deciphera Pharmaceuticals’s revenue for the quarter was up 32.9% compared to the same quarter last year. On average, equities research analysts forecast that Deciphera Pharmaceuticals will post -2.16 EPS for the current year.

Institutional Trading of Deciphera Pharmaceuticals

Hedge funds and other institutional investors have recently modified their holdings of the stock. China Universal Asset Management Co. Ltd. lifted its position in Deciphera Pharmaceuticals by 96.9% during the third quarter. China Universal Asset Management Co. Ltd. now owns 2,026 shares of the company’s stock worth $26,000 after acquiring an additional 997 shares during the last quarter. Quest Partners LLC acquired a new stake in Deciphera Pharmaceuticals during the 4th quarter worth approximately $30,000. AJOVista LLC bought a new stake in Deciphera Pharmaceuticals in the 4th quarter valued at $76,000. Exchange Traded Concepts LLC grew its holdings in Deciphera Pharmaceuticals by 34.0% in the 4th quarter. Exchange Traded Concepts LLC now owns 10,447 shares of the company’s stock valued at $169,000 after buying an additional 2,649 shares in the last quarter. Finally, Aigen Investment Management LP bought a new position in Deciphera Pharmaceuticals during the 3rd quarter worth $181,000. Institutional investors own 70.96% of the company’s stock.

About Deciphera Pharmaceuticals

Deciphera Pharmaceuticals, Inc, a biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response to existing cancer therapies in the United States and internationally. Its lead drug candidate is QINLOCK used for the treatment of gastrointestinal stromal tumors (GIST), as well as in INTRIGUE Phase 3 study to treat second-line GIST.